Jazz Pharmaceuticals (JAZZ) Misses Q2 EPS by 47c; raises guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St futures jump as Democrats sweep midterms
- CVS Health plans to split into two public companies by 2028
- UBS starts bullish coverage on Ferrari Group on luxury logistics growth
- Citi cuts Adobe rating on ’rising risk of a hard reset’
- Apple shares slip amid guidance for tightening margins, slowing services growth
Tweet
Share
E-mail
Get Alerts JAZZ Hot Sheet
Price: $229.74 --0%
Financial Fact:
Net income (loss): 87.15M
Today's EPS Names:
ATS, SICP, FTCO, More
Financial Fact:
Net income (loss): 87.15M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q2 EPS of $5.71, $0.47 worse than the analyst estimate of $6.18. Revenue for the quarter came in at $1.02 billion versus the consensus estimate of $1.11 billion.
GUIDANCE:
Jazz Pharmaceuticals sees FY2026 revenue of $4.600-4.750 billion, versus the consensus of $4.512 billion.
For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- McDonald’s posts better-than-expected third-quarter comparable sales
- Reservoir Media, Inc. (RSVR) Tops Q2 EPS by 2c; offers guidance
- CS Disco, Inc (LAW) Misses Q3 EPS by 6c; offers guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
